9.11. Data Safety Monitoring Board
Phase 2 Pivotal Study CCI 
###TABLE###
 Phase 2 Safety Management Study The DSMB will also meet to review safety data when 20 subjects in Cohort 3, Cohort 4, Cohort 5, and Cohort 6 have been treated with axicabtagene ciloleucel and have had the opportunity to be followed for 30 days, respectively.  The DSMB may meet more often as needed. In addition, Kite Pharma or delegate will submit SAEs or suspected unexpected serious adverse reactions (SUSARs) to the DSMB chair for risk benefit analysis.  The DSMB Chair will review reported SAEs at least monthly and SUSARs as soon as received.